Darinaparsin inhibits prostate tumor-initiating cells and Du145 xenografts and is an inhibitor of Hedgehog signaling

Molecular Cancer Therapeutics

Volumn 14, Issue 1, 2015, Pages 23-30

  Bansal, Nitu ^a   Farley, Nadine Johnson ^a   Wu, Lisa ^a   Lewis, Jonathan ^b   Youssoufian, Hagop ^b   Bertino, Joseph R ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b Ziopharm Oncology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; DARINAPARSIN; DOCETAXEL; MESSENGER RNA; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI2;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MIGRATION; CELL VIABILITY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IN VITRO STUDY; IN VIVO STUDY; LNCAP CELL LINE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TRANSCRIPTION INITIATION; TUMOR CELL; TUMOR INITIATING CELL; TUMOR SPHEROID; TUMOR XENOGRAFT;

EID: 84964290991     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-1040     Document Type: Article

References (18)

1. Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005;23:2396-410.
2. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012;120:1570-80; quiz 752.
3. Mann KK, Wallner B, Lossos IS, Miller WH Jr. Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opin Investig Drugs 2009;18:1727-34.
4. Quintas-Cardama A, Verstovsek S, Freireich E, Kantarjian H, Chen YW, Zingaro R. Chemical and clinical development of darinaparsin, a novel organic arsenic derivative. Anticancer Agents Med Chem 2008;8:904-9.
5. Garnier NRG, Dahabieh MS, Nichol JN, del Rincon SV, Gu Y, Bohle DS, et al. The novel arsenical darinaparsin is transported by cystine importing systems. Mol Pharmacol 2014;85:576-85.
6. Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, et al. A phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clin Cancer Res 2009;15:4769-76.
7. Wu J, Henderson C, Feun L, Van Veldhuizen P, Gold P, Zheng H, et al. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs 2010;28:670-6.
8. Berenson JR, Jagannath S, Boccia R. Phase 1/2 trials of dose and schedule of DARINAPARSIN in multiple myeloma. Hematol J 2007;92:156:PO-609.
9. Matulis SM, Morales AA, Yehiayan L, Croutch C, Gutman D, Cai Y, et al. Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther 2009;8:1197-206.
10. Komarnitsky PB QZ, Schwartz B, Wallner B. ZIO-101 (S-dimethylarsinoglutathione): an oral multi-targeted anti-cancer drug with anti-angiogenic activity. In: Proceedings of the Annual Meeting of the American Association for Cancer Research; 2007; Los Angeles, CA. Philadelphia (PA): AACR; 2007. Abstract nr 4000.
11. Mason TA, Kolobova E, Liu J, Roland JT, Chiang C, Goldenring JR. Darinaparsin is a multivalent chemotherapeutic which induces incomplete stress response with disruption of microtubules and Shh signaling. PloS ONE 2011;6:e27699.
12. Kim J, Lee JJ, Kim J, Gardner D, Beachy PA. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci U S A 2010;107:13432-7.
13. Bansal N, Davis S, Tereshchenko I, Budak-Alpdogan T, Zhong H, Stein MN, et al. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion. Prostate 2014;74:187-200.
14. Chou T. Drug combination studies and their synergy: quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
15. Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest 2011;121:148-60.
16. Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 2013;23:23-34.
17. Tian J, Zhao H, Nolley R, Reese SW, Young SR, Li X, et al. Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer. Clin Cancer Res 2012;18:3366-76.
18. Hosein PJ, Craig MD, Tallman MS, Boccia RV, Hamilton BL, Lewis JJ, et al. A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma. Am J Hematol 2012;87:111-4.